Diabetic autonomic neuropathy: the complication beyond foot pain.

CAN is diagnosed with objective, standardised tests — heart rate variability during deep breathing, the Valsalva manoeuvre, an orthostatic test (the Ewing battery), and, where indicated, further cardiological and gastroenterological assessment. The complaints listed above are not, on their own, a diagnosis, and are not grounds for self-treatment — refer the patient to an endocrinologist or cardiologist.

Chronic stress maintains persistently elevated cortisol levels — a proven inhibitor of insulin action that impairs glucose uptake in tissues and stimulates hepatic glucose production. This is an established endocrinological mechanism, not a hypothesis (Cortisol-Induced Insulin Resistance in Man, J Clin Endocrinol Metab, 1982, and subsequent studies).

Stress management has a measurable, if modest, effect on glycemic control itself. In a randomised study of 53 patients with type 2 diabetes, an eight-week programme of diaphragmatic breathing and progressive muscle relaxation (twice daily) produced a statistically significant reduction in both perceived stress and HbA1c compared with the control group (Koloverou et al., Hormones, 2014). A systematic review of 7 randomised studies in middle-aged and older patients with type 2 diabetes confirms the direction: psychological/stress-reducing interventions lead to a statistically significant but modest reduction in HbA1c compared with standard care (Liu et al., Primary Care Diabetes, 2024).

Stress management is an established addition to type 2 diabetes treatment — alongside medication, insulin and weight control. These studies use breathing, relaxation and psychological techniques; NESA acts on the same mechanism — autonomic balance and the cortisol axis — with an objectively measurable marker (HRV). That is why we expect the same direction with NESA.

The same system that HRV-based CAN diagnostics measure.

NESA XSIGNAL® works with controlled microcurrents aimed at the balance between the sympathetic and parasympathetic nervous system — the same system whose disruption HRV-based CAN diagnostics detect. If a patient's autonomic nervous system achieves better balance, that work is done by the nervous system itself — the device may create conditions that support this process. This adds to glycemic control, endocrinological follow-up and cardiological assessment.

NESA falls into the same broad category as the breathing and relaxation approaches described above — methods aimed at parasympathetic balance, with an established, if modest, benefit in type 2 diabetes. The device itself has not been tested in this direction, but its mechanism logically fits within a well-documented supportive strategy, not a stand-alone treatment.

In diabetic autonomic neuropathy, NESA is an additional, physician-supervised measure — alongside standard diabetes care, at the discretion of the endocrinologist or cardiologist.

This is not the confident "it may help you manage it" register used for milder topics — given the seriousness of the condition, the wording here is deliberately more cautious.